靶向CD19的嵌合抗原受体修饰的T细胞治疗多发性骨髓瘤研究
Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaA patient with refractory multiple myeloma received an infusion of CTL019 cells,
a cellular therapy consisting of autologous T cells transduced with an anti-CD19
chimeric antigen receptor, after myeloablative chemotherapy (melphalan, 140 mg per
square meter of body-surface area) and autologous stem-cell transplantation. Four
years earlier, autologous transplantation with a higher melphalan dose (200 mg per
square meter) had induced only a partial, transient response. Autologous transplantation followed by treatment with CTL019 cells led to a complete response with no evidence of progression and no measurable serum or urine monoclonal protein at the most recent evaluation, 12 months after treatment. This response was achieved
despite the absence of CD19 expression in 99.95% of the patient’s neoplastic plasma
cells.
靶向CD19的嵌合抗原受体修饰的T细胞治疗多发性骨髓瘤研究
一个难治性多发性骨髓瘤患者接受CTL019细胞输注，一种细胞治疗方案包括：使用靶向CD19嵌合抗原受体修饰的自体T细胞治疗，之后清髓化疗（马法兰，140毫克平方米体表面积）和自体干细胞移植后。四年之前，高剂量美法仑处理（200毫克每平方米）和自体移植所引起的只有部分的，短暂的效果。CTL019细胞处理以后使用自体移植会产生一个完整的疗效，在最近的测量评估中（也就是治疗后的12个月），病人伴随着无疾病进展生存，并且检测不到血清/尿单克隆蛋白。虽然病人肿瘤细胞99.95%表面CD19表达缺失，但是这个疗效仍然能够完成。
出自爱康得
页:
[1]